SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Beltropolis Boy who wrote (1082)7/13/1999 5:43:00 PM
From: Biomaven  Read Replies (1) | Respond to of 1686
 
Copithorne also points out that these new drugs are not expected to have the same sales potential as Avonex.

So much for that analyst. <g> I don't know if Antova is going to be successful, but I do know that if it is, it will be a much bigger drug than Avonex. Ah well, maybe she was misquoted.

Boy, these guys can't even write a decent bearish article. (Not that I care for the bullish ones either, but the bearish ones should be so much easier to write.)

Peter



To: Beltropolis Boy who wrote (1082)7/13/1999 5:57:00 PM
From: JEB  Respond to of 1686
 
I know Vincent said he wouldn't buy another company but I wish he would re-consider, IMCL would make this company a blockbuster but would be tough to buy, even for cash rich BGEN.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News